Ophthotech Raises $175M for Solo Run in Phase III
By Catherine Shaffer
Tuesday, May 28, 2013
At a time when a majority of biotech companies are partnering up with big pharma for Phase III trials, Ophthotech Corp., of Princeton, N.J., is building a war chest to go it alone.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.